Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
53,287,730
-
Share change
-
+1,125,462
-
Total reported value
-
$812,631,603
-
Price per share
-
$15.25
-
Number of holders
-
65
-
Value change
-
+$13,608,742
-
Number of buys
-
46
-
Number of sells
-
19
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q2 2018
As of 30 Jun 2018,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,287,730 shares.
The largest 10 holders included
Crestline Management, LP, FMR LLC, BAILLIE GIFFORD & CO, FIL Ltd, Temasek Holdings (Private) Ltd, VANGUARD GROUP INC, BlackRock Inc., BAMCO INC /NY/, Alphabet Inc., and Artal Group S.A..
This page lists
65
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.